FDA Clearance Tracker · P120012
ABBOTT REALTIME HCV GENOTYPE II, ABBOTT REALTIME HCV GENOTYPE II CONTROL KIT, URACIL-N-GLYCOSYLASE (UNG)
Last checked: Nov 20, 2026Latest source record: Jun 20, 2013 (this decision)Source: openFDAMethods & limitations
Decided
Jun 20, 2013
Approved (reclassified)
Time to decision
343 days
Received Jul 12, 2012. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class II
The decision
- FDA number
- P120012
- Device name
- ABBOTT REALTIME HCV GENOTYPE II, ABBOTT REALTIME HCV GENOTYPE II CONTROL KIT, URACIL-N-GLYCOSYLASE (UNG)
- Applicant
- Abbott Molecular
- Applicant location
- Des Plaines, IL
- Received
- Jul 12, 2012
- Decided
- Jun 20, 2013
- Decision
- Approved (reclassified)
- Supplements
- 18 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Assay, genotyping, hepatitis c virus (OBF)
- Device class
- Class II
- Regulation
- 21 CFR 866.3170
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE ABBOTT REALTIME HCV GENOTYPE II, ABBOTT REALTIME HCV GENOTYPE II CONTROL KIT, AND URACIL-GLYCOSYLASE(UNG). THIS DEVICE IS INDICATED FOR: ABBOTT REALTIME HCV GENOTYPE IITHE ABBOTT REALTIME HCV GENOTYPE II IS AN IN VITRO REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION (RT-PCR) ASSAY FOR USE WITH THE ABBOTT MSAMPLE PREPARATION SYSTEM REAGENTS AND WITH THE ABBOTT M2000SP AND M2000RT INSTRUMENTS FOR THE QUALITATIVE IDENTIFICATION OFHEPATITIS C VIRUS (HCV) GENOTYPES 1, 1A, 1B, AND 2 - 5 IN PLASMA OR SERUM FROM INDIVIDUALS CHRONICALLY INFECTED WITH HCV.THE ABBOTT REALTIME HCV GENOTYPE II IS INTENDED FOR USE AS AN AID IN THE MANAGEMENT OF HCV-INFECTED INDIVIDUALS AND IN GUIDING THE SELECTION OF THERAPEUTIC TREATMENT INDICATED FOR THE ABOVE LISTED GENOTYPES. THE ASSAY IS INTENDED FOR USE ON PATIENTS WHO ARE CHRONICALLY INFECTED WITH HCV, ARE BEING CONSIDERED FOR ANTIVIRAL TREATMENT, AND ARE POSITIVE FOR HCV RNA. THE ABBOTT REALTIME HCV GENOTYPE II ASSAY IS NOT FOR SCREENING BLOOD, PLASMA, SERUM OR TISSUE DONORS FOR HCV. ABBOTT REALTIME HCV GENOTYPE II CONTROL KITTHE ABBOTT REALTIME HCV GENOTYPE II CONTROLS ARE USED TO ESTABLISH RUN VALIDITY OF THE ABBOTT REALTIME HCV GENOTYPE II ASSAY WHEN USED FOR DETERMINING THE GENOTYPE(S) OF HEPATITIS C VIRUS (HCV) IN PLASMA OR SERUM FROM INDIVIDUALS CHRONICALLY INFECTED WITH HCV. URACIL-N-GLYCOSYLASE (UNG) THE URACIL-N-GLYCOSYLASE (UNG) PROCEDURE IS TO BE USED IN CONJUNCTION WITH ABBOTT REALTIME HCV GENOTYPE II ASSAY AS AN OPTIONAL CONTAMINATION CONTROL FOR CUSTOMER LABORATORIES THAT ARE CURRENTLY USING OR HAVE PREVIOUSLY USED AMPLIFICATION TECHNOLOGIES THATINCORPORATE URACIL INTO THE AMPLIFICATION PRODUCT.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code OBF (Assay, genotyping, hepatitis c virus).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Abbott Molecular
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Alinity m HCV510(k)
K252102 · Decided Sep 25, 2025 · 84 days after receipt
Device type: Assay, Hybridization And/Or Nucleic Acid Amplification For Detection Of Hepatitis C Rna,Hepatitis C Virus (MZP) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.